Drug intelligence / Profile preview

DTX-102

Development stage: Preclinical
Lead developer: Dualitas Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DTX-102 is a preclinical-stage bispecific antibody being developed by Dualitas Therapeutics (formerly Dual Therapeutics) for the treatment of autoimmune diseases, including arthritis. The drug is one of the lead programs utilizing the company's proprietary 'E1' Proximity Engager mechanism. This mechanism is designed to bring specific molecular targets into proximity to modulate immune responses, although the exact biological targets for DTX-102 have not been publicly disclosed. As of early 2024, the program is in the lead generation and optimization phase of preclinical development.

Beyond the preview

Go deeper on DTX-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTX-102.

Explore the full profile